Power your decentralized trial with an agile randomization and trial supply management solution that supports supply flexibility and optimization as well as adaptable direct to patient options.
Preparing for a regulatory inspection that includes your randomization and trial supply management (RTSM), commonly referred to as interactive response technology (IRT), during a clinical trial can be daunting, but there’s much that can be done to be ready for success. Read on to learn about the importance of clear roles, audit trails, data integrity, and training, and get recommendations to help you stay inspection ready.
Why prepare for an RTSM regulatory inspection?
Inspections are increasing in length of time and becoming more frequent. We expect this trend to continue as the FDA and other agencies resolve their backlogs, so now is the time to evaluate your preparedness.
As Figure 1 indicates, the number of inspections supported by IQVIA involving IRT systems has steadily increased since 2021. We see the trend continuing in 2025.
Figure 1. Intensifying frequency of inspections
What are the steps to prepare for an RTSM regulatory inspection?
Here are some key principles I’ve compiled from nearly two decades of quality management experience in clinical software and services, including hands-on experience across scores of IRT inspections and audits.
We all know that inspections are fast paced, but keep in mind that they are also risk based. Inspectors want to see evidence of client oversight and system validation. Keep all your data and processes organized and accessible.
Understanding your team’s responsibilities during a clinical trial can save everyone a lot of time during a live inspection. Clearly define who is responsible for the data, as well as what will be reviewed in an inspection and why, so that if the time comes, you and your team can efficiently address questions and manage risks.
Remember: The principal investigators hold responsibility for the subject and patient data. Any data changes during an inspection must be made with PI awareness and approval, always prioritizing patient rights and good clinical practice principles.
Regulations require audit trail reviews, so it’s important to prepare the person who is responsible. Given that IRT is a highly transactional system, the frequency of reviews may differ from other systems. Audit trails are not just a regulatory checkbox — they help you and the inspectors investigate any issues that arise.
Data integrity is another important element in an inspection. Underlying documentation and strong control procedures are critical to the outcome of your inspection and throughout the study lifecycle. Ensure data-integrity elements are built into your quality management system.
Figure 2. Ensuring data integrity and reliability
New regulatory guidance
In 2023, the European Medicines Agency (EMA) released new guidance on computer systems and electronic records that are used in clinical trials. This document is essential to ensuring a smooth inspection. We strongly recommend to our clients that they conduct a gap assessment with this document in hand. These assessments allow you to understand your audit trails in the context of compliance risk. Look at the guidance, identify your own areas of weakness and strength, and make sure you can readily address each point within the EMA document. The earlier you establish a position on these points, the better.
Training your teams should go beyond compliance — every team member should understand how their work supports inspections. Some additional tips include:
As clinical trials grow in complexity, randomization in IRT systems faces increased scrutiny. It’s essential to know your audience and maintain the blind. Inspectors are usually considered unblinded, but your clients often are not. Always confirm who is present in open sessions before sharing sensitive information and ask blinded individuals to step out if needed. Be ready to share randomization assignments and ensure you have documented procedures for setup, software development life cycle processes, system changes, and updates.
If you’ve been notified that an inspection is going to take place, here are the actions you should take to help the process go smoothly:
These recommendations and steps — from data access to response review — are closely tied together. It’s critical to remember that we don’t implement these measures just because they’re required by regulations but rather because they also make our day-to-day work easier. When we remain organized, with consistent oversight, data integrity, audit trails and controls, we can be prepared for any inspection.
How can an RTSM system provider help?
Knowing you work with an IRT system and services provider that offers responsive, knowledgeable support can also help alleviate some of the inspection burden. For a more detailed discussion on this topic, please access this on-demand webinar I recorded in March 2025:
Ensuring a successful regulatory inspection with support from your IRT provider
You can learn more and contact us about IQVIA IRT at www.iqvia.com/IRT.
Justine Koor joined Cenduit in 2008 and has been a part of IQVIA and the IQVIA IRT leadership team since 2013. Justine is a quality professional with over 20 years of experience in computerized systems validation and auditing and quality systems management. With a career that began in operations prior to moving to quality, she understands the day-to-day efforts and what quality can bring to operations teams. She utilizes her experience by supporting sponsors in completing successful regulatory inspections related to IRT and computer systems.
Additionally, Justine is responsible for the operational activities of the quality assurance department and the development and maintenance of all aspects of the quality system.
She is a data protection champion and is CIPM certified. Justine is dedicated to helping teams identify and implement data protection laws into everyday practices. She is based in Basel, Switzerland.
Published on PharmaPhorum by Cara Woodruff, Director of Product Management, IQVIA IRT
Save upwards of $20,000 a month through automated supply optimization
Power your decentralized trial with an agile randomization and trial supply management solution that supports supply flexibility and optimization as well as adaptable direct to patient options.
Fast, flexible and proven, IQVIA’s industry-leading electronic clinical outcome assessment (eCOA) platform ramps up efficiencies, delivers real-time data, and sharpens insights through best-in-class technology and a better patient experience.
Deliver eConsent to sites and study participants around the globe with confidence